Obermatt
See Similar Stocks →

Ebos

NZC:EBO · NZEBOE0001S6
Health Care Providers & ServicesLarge

360

40
EV / EBIT75
Price / Owner Earnings35
Owner Earnings Yield63
Dividend Yield97
Price/Sales90
EV / Gross Profit82
Price/Book60
Return on Capital71
Cash Return on Capital43
Return on Equity55
EBIT Margin31
Gross Profitability49
Cash Conversion23
Accruals21
Owner Earnings Margin40
Sales growth9
Profit Growth63
Long-Term EPS Growth42
Owner Earnings Growth36
Reinvestment21
Price momentum4
Debt load28
Refinancing59
Debt Payback32
Liquidity20
Analyst ratings81
Opinion Changes50
Price Target Upside96
Market mood75
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ebos clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryAustralia
IndustryHealth Care Providers & Services
SizeLarge
TypePublic Company
ExchangeNZSE
Founded1922
Employees464
Websiteebosgroup.com
ISINNZEBOE0001S6
Last UpdateApr 2, 2026
Indices
ASX 200 (Australia)ASX 300 (Australia)NZSX 50 (New Zealand)
Themes
Health DiagnosticsPet CareAnimal FeedNutraceuticalPet Food and SuppliesHealth CareHospital

Description

EBOS Group Limited (EBOS) engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. Business Segments The company operates through Healthcar…

Analysis

Bargain bin

EBOS Group Limited is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

On valuation, the picture is fair. The owner-earnings multiple stands at 20.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 3%. The gap between price and consensus is worth watching: demanding expectations.

Growth is tepid; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
36
2023202420252026

All-time high

77

Jan 2023

All-time low

12

Oct 2024

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
90
51
66
61
Price/Earnings
71
17
23
16
Price/Book
60
14
17
23
Dividend Yield
97
87
56
55
Value (overall)
92
63
13
20

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ebos with its peers
Sigma Healthcare
ASX:SIG
60
CountryAustralia
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →
Sinopharm
HKG:1099
73
CountryChina
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Australian Clinical Labs
ASX:ACL
65
CountryAustralia
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Healius
ASX:HLS
20
CountryAustralia
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Ramsay Health Care
ASX:RHC
15
CountryAustralia
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Raffles Medical Group
SES:BSL
70
CountrySingapore
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →